Table 1 Characteristics of all included studies (Alphabetically ordered)
Study | Treatment | n | Mean age (yrs) | Baseline WOMAC score (SD) | Change from baseline WOMAC score (SD) | Percentage women | Duration OA at baseline (yrs) | Flare required | Concomitant analgesic allowedd | OA site |
|---|---|---|---|---|---|---|---|---|---|---|
Abou-Raya et al. 2012 [49]b | Duloxetine | 144 | 68.9 | 50.63 (9.56) | -12.40 (14.02) | 16 | 5.7 | No | Yes | Knee |
| Â | Placebo | 144 | 68.5 | 50.94 (9.47) | -3.96 (15.24) | 17 | 5.6 | Â | Â | Â |
Afilalo et al. 2010 [50]f | Oxycodone 40–100 mg | 342 | 58.2 |  | -27.50 (21.75) | 59 |  | No | Not mentioned | Knee |
Study NCT00421928 | Placebo | 337 | 58.2 | Â | -22.50 (21.00) | 59 | Â | Â | Â | Â |
Baerwald et al. 2010 [51]b | Naproxen 1000Â mg | 156 | 62.26 | Â | -22.54 (20.40) | 32.1 | Â | Yes | No | Hip |
| Â | Placebo | 331 | 63.29 | Â | -14.80 (22.27) | 37.2 | Â | Â | Â | Â |
Bensen et al. 1999 [52] | Celecoxib 200Â mg | 202 | 63 | 53.13 (17.08) | -12.50 (18.06) | 72 | 9 | No | No | Knee |
| Â | Naproxen 1000Â mg | 198 | 62 | 55.10 (14.58) | -12.40 (18.91) | 71 | 10 | Â | Â | Â |
| Â | Placebo | 203 | 62 | 53.85 (15.42) | -6.35 (16.18) | 75 | 11 | Â | Â | Â |
Bingham et al. 2007a [53] | Etoricoxib 30Â mg | 231 | 62.1 | 65.40 (13.03) | -24.37 (21.37) | 66.2 | Â | Yes | No | Hip/knee |
| Â | Celecoxib 200Â mg | 241 | 62.5 | 66.20 (13.24) | -22.21 (21.66)a | 69.7 | Â | Â | Â | Â |
| Â | Placebo | 127 | 62.8 | 64.67 (13.30) | -10.98 (22.14)a | 65.4 | Â | Â | Â | Â |
Bingham et al. 2007b [53] | Etoricoxib 30Â mg | 244 | 61.9 | 67.23 (13.24) | -24.37 (22.19) | 69.7 | Â | Yes | No | Hip/knee |
| Â | Celecoxib 200Â mg | 247 | 62.2 | 65.59 (14.59) | -23.19 (23.29)a | 61.9 | Â | Â | Â | Â |
| Â | Placebo | 117 | 60.9 | 64.98 (13.81) | -12.29 (22.63)a | 65 | Â | Â | Â | Â |
Boswell et al. 2008 [54] | Celecoxib 200Â mg | 185 | 59.7 | 63.55 (14.70) | -23.46 (24.51)a | 67 | 8.8 | No | No | Knee |
| Â | Placebo | 186 | 60.5 | 63.37 (13.68) | -18.46 (23.46)a | 73 | 8 | Â | Â | Â |
Burch et al. 2007 [55]f | Tramadol 200–300 mg | 432 | 62 |  | 34.96 (14.74)g | 64 |  | Yes | No | Knee |
Study NCT00833794 | Placebo | 214 | 62 | Â | 35.20 (15.13)g | 62 | Â | Â | Â | Â |
Chappell et al. 2011 [26]b | Duloxetine 60–120 mg | 128 | 63.16 | 51.63 (10.45) | -20.50 (11.87) | 70 | 8.14 | No | Yes | Knee |
Study NCT00433290 | Placebo | 128 | 61.9 | 53.82 (9.04) | -16.25 (12.26) | 84 | 6.74 | Â | Â | Â |
Chappell et al. 2009 [27]b | Duloxetine 60–120 mg | 111 | 62.07 | 57.10 (12.15) | -24.01 (16.07) | 63.06 | 9.04 | No | Yes | Knee |
Study NCT00408421 | Placebo | 120 | 62.48 | 56.51 (11.12) | -16.81 (13.67) | 67.5 | 9.3 | Â | Â | Â |
Clegg et al. 2006 [56]b, e | Celecoxib 200Â mg | 318 | 59.4 | 47.10 (13.36) | -17.95 (14.98) | 66.7 | 10.1 | No | Yes | Knee |
| Â | Placebo | 313 | 58.2 | 46.23 (13.49) | -14.58 (15.99) | 63.9 | 9.5 | Â | Â | Â |
DeLemos et al. 2011 [57] | Tramadol 200Â mg | 199 | 62 | 61.13 (14.02) | -16.24 (24.22) | 62.3 | 8.5 | No | No | Hip/knee |
| Â | Tramadol 300Â mg | 199 | 59.7 | 60.37 (15.93) | -22.10 (24.16) | 61.8 | 7.6 | Â | Â | Â |
| Â | Celecoxib 200Â mg | 202 | 60 | 58.21 (15.26) | -25.60 (24.58) | 64.9 | 8 | Â | Â | Â |
| Â | Placebo | 200 | 58.9 | 59.95 (15.49) | -17.73 (24.28) | 68.5 | 7.8 | Â | Â | Â |
Essex et al. 2012 [58]c | Celecoxib 200Â mg | 296 | 60 | 56.15 (15.42) | -23.13 (19.71) | 64.9 | 7.2 | Yes | No | Knee |
| Â | Naproxen 1000Â mg | 293 | 60.7 | 56.56 (15.73) | -23.54 (19.61) | 67.6 | 8.5 | Â | Â | Â |
Fishman et al. 2007 [59] | Tramadol 200Â mg | 107 | 61 | 58.42 (13.99) | -24.39 (21.19)a | 59.8 | Â | No | Yes | Knee |
| Â | Tramadol 300Â mg | 105 | 60 | 63.74 (15.21) | -25.54 (44.61) | 65.7 | Â | Â | Â | Â |
| Â | Placebo | 224 | 61 | 61.29 (14.16) | -18.82 (38.32) | 61.6 | Â | Â | Â | Â |
Fleischmann et al. 2006 [60]b | Celecoxib 200Â mg | 444 | 61.3 | 50.94 (16.76) | -16.67 (18.95) | 67.1 | 6.7 | No | No | Knee |
| Â | Placebo | 231 | 61.5 | 48.65 (16.97) | -9.69 (16.82) | 66.2 | 6.6 | Â | Â | Â |
Fleischmann et al. 2001 [61]b | Tramadol 200–400 mg | 63 | 62.52 |  | 41.60 (20.50)g | 65.1 | 7.94 | Yes | No | Knee |
| Â | Placebo | 66 | 62.45 | Â | 50.40 (22.50)g | 59.1 | 7.76 | Â | Â | Â |
Gana et al. 2006 [36] | Tramadol 200Â mg | 201 | 59.1 | 63.77 (13.14) | -21.25 (23.92) | 63.7 | 7.7 | No | No | Hip/knee |
| Â | Tramadol 300Â mg | 201 | 58.5 | 60.10 (14.73) | -20.27 (23.81) | 59.2 | 8 | Â | Â | Â |
| Â | Placebo | 205 | 56.4 | 61.82 (14.82) | -14.19 (23.45) | 68.8 | 7.7 | Â | Â | Â |
Hochberg et al. 2011a [62] | Celcoxib 200Â mg | 242 | 33.2 | Â | -5.56 (40.51)a, h | 61.2 | Â | Yes | Yes | Knee |
| Â | Placebo | 124 | 32.7 | Â | Â | 66.1 | Â | Â | Â | Â |
Hochberg et al. 2011b [62] | Celecoxib 200Â mg | 244 | 33 | Â | -4.36 (41.89)a, h | 62.7 | Â | Â | Â | Knee |
| Â | Placebo | 122 | 33 | Â | Â | 63.1 | Â | Â | Â | Â |
Kivitz et al. 2002 [63] | Naproxen 1000Â mg | 205 | 60.4 | 55.91 | -18.79 (19.78) | 63 | 9.4 | No | No | Knee |
| Â | Placebo | 205 | 60.3 | 55.72 | -14.04 (19.71) | 64 | 8.3 | Â | Â | Â |
Kivitz et al. 2001 [64] | Celecoxib 200Â mg | 207 | 62 | 52.29 (16.73) | -10.10 (15.92) | 65 | 7.2 | Yes | No | Hip |
| Â | Naproxen 1000Â mg | 207 | 64 | 51.88 (17.24) | -11.98 (16.07) | 66 | 7.3 | Â | Â | Â |
| Â | Placebo | 218 | 64 | 52.81 (15.60) | -4.38 (15.70) | 67 | 7.9 | Â | Â | Â |
Lehmann et al. 2005 [65]b | Celecoxib 200Â mg | 420 | 62.9 | 52.60 (14.93) | -15.31 (16.47) | 68.3 | 4.4 | Yes | yes | Knee |
| Â | Placebo | 424 | 61.7 | 51.77 (15.09) | -11.77 (19.03) | 71.9 | 3.9 | Â | Â | Â |
Leung et al. 2002 [66] | Etoricoxib 60Â mg | 224 | 62.93 | 63.84 (13.89) | -22.19 (15.91) | 77.2 | 5.88 | Yes | No | Hip/knee |
| Â | Naproxen 1000Â mg | 221 | 63.16 | 63.76 (13.36) | -21.91 (15.81) | 78.3 | 6.25 | Â | Â | Â |
| Â | Placebo | 56 | 64.09 | 68.11 (10.83) | -13.26 (15.17) | 82.1 | 6.3 | Â | Â | Â |
Markenson et al. 2005 [67]b, e | Oxycodone 10–120 mg | 56 | 62 | 64.70 (15.71)a | -14.93 (26.09) | 68 |  | No | Yes | Hip/knee/spine/other |
| Â | Placebo | 51 | 64 | 63.80 (15.00) | -0.87 (19.72) | 78 | Â | Â | Â | Â |
Puopolo et al. 2007 [68] | Etoricoxib 30Â mg | 224 | 62.1 | 64.95 | -24.90 (23.14) | 77.7 | 6.6 | Yes | Yes | Hip/knee |
| Â | Ibuprofen 2400Â mg | 213 | 62.3 | 63.18 | -21.73 (22.49) | 73.7 | 6.7 | Â | Â | Â |
| Â | Placebo | 111 | 64 | 64.56 | -14.43 (21.23) | 75.7 | 6.5 | Â | Â | Â |
Rauck et al. 2013 [69] | Hydromorphone 16Â mg | 330 | 59.5 | Â | -17.00 (19.98) | 64.2 | Â | No | Yes | Hip/knee |
| Â | Placebo | 331 | 60 | Â | -13.00 (20.01) | 63 | Â | Â | Â | Â |
Schnitzer et al. 2011 [70]b | Celecoxib 200Â mg | 419 | 61.7 | 54.90 (14.49) | -16.58 (15.24)a | 61.3 | 3.7 | No | No | Hip |
| Â | Placebo | 416 | 61.4 | 54.58 (15.11) | -10.62 (13.83)a | 60.6 | 3.8 | Â | Â | Â |
Schnitzer et al. 2011 [71]b | Naproxen 1000Â mg | 254 | 60 | Â | -26.29 (18.71)a | 70.5 | Â | Yes | No | Knee |
| Â | Placebo | 257 | 60.15 | Â | -16.04 (18.62)a | 72.65 | Â | Â | Â | Â |
Schnitzer et al. 2010 [72]b | Naproxen 1000Â mg | 227 | 61.1 | 70.08 (12.98) | -33.33 (20.23)a | 67.4 | Â | Yes | No | Knee |
| Â | Placebo | 221 | 61 | 69.85 (13.12) | -20.42 (20.17)a | 71.9 | Â | Â | Â | Â |
Sheldon et al. 2005 [73]b | Celecoxib 200Â mg | 393 | 60.2 | 54.79 (15.45) | -16.25 (19.08) | 63.1 | 6.7 | No | No | Knee |
| Â | Placebo | 382 | 60.8 | 55.31 (14.36) | -9.90 (17.01) | 61.3 | 7 | Â | Â | Â |
Sowers et al. 2005 [74]c | Celecoxib 200Â mg | 136 | 61.8 | 46.20 (22.16) | -16.30 (20.99) | 62 | Â | No | No | Hip/knee |
| Â | Naproxen 1000Â mg | 128 | 63.6 | 51.40 (20.36) | -14.70 (21.50) | 60 | Â | Â | Â | Â |
Tannenbaum et al. 2004 [75]b | Celecoxib 200Â mg | 481 | 64.1 | 50.73 (16.04) | -13.96 (16.46) | 69.2 | 5.3 | No | No | Knee |
| Â | Placebo | 243 | 64.6 | 51.25 (14.58) | -9.79 (16.77) | 67.1 | 4.3 | Â | Â | Â |
Vojtassak et al. 2011 [76] | Hydromorphone | 138 | 65 | 60.00 (10.11) | -17.75 (14.62) | 77 | Â | No | Yes | Hip/knee |
| Â | Placebo | 149 | 66 | 57.92 (10.36) | -17.69 (15.79) | 68 | Â | Â | Â | Â |
Wiesenhutter et al. 2005 [77] | Etoricoxib 30Â mg | 214 | 63.1 | 68.68 (16.64) | -24.52 (22.97) | 70.1 | 7.9 | Yes | No | Hip/Knee |
| Â | Ibuprofen 2400Â mg | 210 | 61.3 | 68.13 (17.02) | -23.65 (23.13) | 70 | 8.2 | Â | Â | Â |
| Â | Placebo | 104 | 59.5 | 69.71 (16.52) | -14.20 (20.24) | 72.1 | 6.9 | Â | Â | Â |